Abstract
Background
The aim of this study was to assess the efficacy of radioactive iodine-131 (131I) therapy for lymph node metastasis of differentiated thyroid cancer (DTC) and to identify influential factors using univariate and multivariate analyses to determine if identified factors influence the efficacy of treatment.
Material/Methods
This study included a retrospective review of 218 patients with histologically proven DTC in the post-operation stage. After thyroid tissue remnants were eliminated with 131I therapy, patients’ lymph node status was confirmed by ultrasound and by 131I whole body scan regarding lymph node metastasis, and then patients were treated with 131I as appropriate. The treatment efficacy was assessed and possible influencing factors were identified using univariate and multivariate analyses.
Results
The total effective rate of 131I therapy was 88.07% (including a cure rate of 20.64% and an improvement rate of 67.43%). The non-effective rate was 11.93%. Of the total 406 lymph nodes of 218 patients, 319 lymph nodes (78.57%) were judged to be effectively cured, including 133 (32.75%) lymph nodes that were totally eliminated and 186 (45.82%) lymph nodes that shrank. Eighty-seven (21.43%) of the 406 lymph nodes had no obvious change. No lymph nodes were found to be in a continuously enlarging state. Distant metastasis, size of lymph node, human serum thyroglobulin (HTG) level, and condition of thyroid remnants ablation were identified as the independent factors influencing the efficacy of treatment using univariate and multivariate analyses.
Conclusions
The use of 131I is a promising treatment for lymph node metastasis of DCT. Distant metastasis, size of lymph nodes, HTG level, and condition of thyroid remnant ablation were independent factors influencing the treatment efficacy.
MeSH Keywords: Iodine Isotopes, Lymph Nodes, Thyroid Neoplasms
Background
Differentiated thyroid cancer (DTC) includes papillary thyroid cancer and follicular thyroid cancer. DTC incidence tops the list of cancers of the human endocrine system and DTC rates are increasing every year [1,2]. Studies have confirmed the efficacy of 131I in ablation of thyroid remnants, treatment of metastasis after ablation operation, and as a prognostic indicator [3–5]. Three stages of treatment of DRC have been suggested as optimal treatment strategies: the total or subtotal ablation of thyroid tissues, the postoperative ablation of thyroid remnants with 131I therapy, and the administration of thyroid hormone suppression treatment. Follow-up metrics for DTC patients include thyroglobulin (HTG) levels, single-photon emission computed tomography (SPECT)/CT, ultrasound, chest CT, and 131I whole body scan. DTC generally has a good prognosis, but lymph node metastasis may occur at an early stage, which can have a negative impact on the prognosis of DTC. Many studies have shown that the metastasis rate of cervical lymph nodes ranges from 15% to 80% [7–9]. Nevertheless, 131I is still regarded as a common method for treating lymph node metastasis of DTC. Due to the lack of studies about 131I treatment efficacy and its influencing factors, our study aimed to analyze these two aspects of 131I therapy of lymph node metastasis of DTC.
Material and Methods
Clinical materials
We conducted a retrospective analysis of 218 patients with histologically proven DTC after thyroidectomy, of which 187 patients had papillary thyroid cancer and 31 patients had follicular thyroid cancer. Of the 218 patients, 64 were male and 154 were female; the average age ranged from 32 to 56 (43.73±12.12) years. Treatment for 94 patients was with total thyroidectomy or subtotal thyroidectomy, while the remaining 124 patients underwent a combination of total thyroidectomy and cervical lymph node dissection (of which 76 patients had unilateral lymph node dissection and 48 patients had bilateral lymph node dissection). After treatment with 131I for ablation of thyroid remnants (with a dosage of 3.7 GBq), 406 lymph nodes of 218 patients were found to have metastases using ultrasound and therapeutic-dosage 131I whole body scan. Three hundred and forty-seven lymph nodes were <2 cm and 59 lymph nodes were ≥2 cm; the largest lymph node was 3.4×2.5×1.9 cm.
Treatment methods
Lymph node metastasis in DTC patients were treated with 5.55 GBq 131I. Before the 131I therapy, all patients were asked to stop taking Euthyrox for at least 3 weeks prior to 131I therapy to ensure thyroid-stimulating hormone (TSH) levels were >30 uIU/mL). All patients had routine blood tests (TSH, HTG, and HTGAb), and chest radiograph, cervical neck ultrasound, and 131I whole body scan (185 MBq). After a week of 131I therapy, the patients were given prednisone and vitamin C to mitigate local symptoms as well as to protect their salivary glands and parotid glands [12]. On the sixth day of 131I therapy, the patients were given a therapeutic-dosage 131I whole body scan, and if the patients showed no signs of getting better after the first course of treatment, the second therapeutic activity was administered under the same conditions only with 5.55 GBq 131I. All patients had ≤2 treatments.
Criteria of treatment efficacy
Methods to assess the efficacy of 131I for treating lymph node metastasis of DTC include HTG level, ultrasound, and therapeutic-dosage 131I whole body scan. The criteria for treatment efficacy were as follows:
Cure Rate (CR). The lymph nodes disappeared after 131I therapy as seen by ultrasound; former lesions showed no 131I uptake on whole body scan; and HTG level was <2 μg/mL.
Improvement Rate (PR). The shrinkage and removal of lymph nodes were shown on ultrasound; the 131I whole body scan showed images of lesions that were faded; and the HTG level decreased, but was still ≥2 μg/mL.
Non-effective Rate (NR). The lymph nodes did not shrink but tended to enlarge in size or increase in number; no obvious changes or no signs of densification were shown on 131I whole body scan; and no changes were seen in HTG level. If a patient presented with several metastatic lymph nodes, the ineffectiveness of treatment was defined as either of the following: enlargement of any single lymph node, or increase in lymph node number.
Observation factors
The influences of nine factors on treatment efficacy were analyzed and included: age, gender, pathological type of cancer (papillary cancer or follicular cancer), operation methods, condition of distant metastasis, number of metastatic lymph nodes, number of lymph nodes, HTG level, and condition of thyroid remnant ablation. All tissue samples were provided and recorded by clinical doctors with over 10 years experience treating lymph node metastasis of DTC with 131I therapy.
This study was approved by the Hebei Medical University Ethical Committee, Hebei, China. The nature, purpose, and potential risks of the study were explained to each participant prior to enrollment. Written informed consent was obtained from all enrolled patients.
Statistical analysis
All statistics were analyzed using the SPSS 17.0 statistical software package. The univariate analysis was conducted through chi-square test, and the multivariate analysis through logistic regression analysis.
Results
Treatment efficacy of 131I to lymph node metastasis
The 218 patients with lymph node metastasis of DTC underwent 131I therapy once or twice. Of these, 45 patients became free of disease with a cure rate of 20.64%; 147 patients had improved conditions, for an improvement rate of 67.43%; and 26 patients were treated non-effectively; thus, the total effective rate (cure plus improvement) for 131I therapy was 88.07%, and the non-effective rate was 11.93%. Of the total 406 lymph nodes, 319 (78.57%) were treated effectively: 133 (32.75%) were totally removed after 131I therapy, and 186 (45.82%) had shrunk. In addition, 87 (21.43%) of the 406 lymph nodes had no obvious changes, and none of lymph nodes were found to be in a continuously enlarged state.
Results of univariate analysis
The univariate analysis showed that age, condition of distant metastasis, size of lymph nodes, number of lymph nodes, HTG level, and condition of first-time thyroid remnant ablation had statistical significance, while gender, pathological type, and operation method had no statistical significance (Table 1).
Table 1.
Results of univariate analysis.
| Influencing Factors | Number of patients | χ2 | P | |
|---|---|---|---|---|
| Age | ≥45 years old | 124 | 4.436 | 0.035 |
| <45 years old | 94 | |||
| Gender | Male | 64 | 0.024 | 0.878 |
| Female | 154 | |||
| Pathological types | Papillary cancer | 187 | 2.956 | 0.086 |
| Follicular cancer | 31 | |||
| Operation methods | Total or subtotal thyroidectomy | 94 | 2.589 | 0.108 |
| Total thyroidectomy and lymphadenectomy | 124 | |||
| Distant metastasis | Yes | 40 | 30.574 | 0.000 |
| No | 178 | |||
| Number of lymph nodes | >1 | 116 | 4.756 | 0.029 |
| ≤1 | 102 | |||
| Size of lymph node | ≥2 cm | 53 | 9.387 | 0.002 |
| <2 cm | 165 | |||
| HTG | ≥5 μg/L | 157 | 54.497 | 0.000 |
| <5 μg/L | 61 | |||
| Condition of thyroid remnants ablation with 131I | Total ablation | 177 | 12.501 | 0.000 |
| Subtotal ablation | 41 |
Results of multivariate analysis
Factors from the univariate analysis that showed significant influence on treatment efficacy were then used in a logistic multivariate regression analysis model; the factors used were: age, condition of distant metastasis, size of lymph nodes, number of lymph nodes, HTG level, and condition of thyroid remnant ablation with 131I. As a result, the condition of distant metastasis, size of lymph nodes, HTG level, and condition of thyroid remnant ablation with 131I were defined as independent factors influencing the efficacy of treatment (p<0.05) (Table 2).
Table 2.
Results of multivariate analysis.
| Influencing Factors | B | S.E. | Wald | P | Exp(B) | 95.0% CI for EXP(B) |
|---|---|---|---|---|---|---|
| Distant metastasis | −2.209 | 0.564 | 15.333 | 0.000 | 0.110 | 0.036~0.332 |
| Size of lymph node | −1.232 | 0.557 | 4.894 | 0.027 | 0.292 | 0.098~0.869 |
| HTG | −2.377 | 0.553 | 18.511 | 0.000 | 0.093 | 0.031~0.274 |
| Condition of first-time remnants ablation | −1.116 | 0.566 | 30887 | 0.049 | 0.328 | 0.108~0.993 |
Discussion
The differentiated thyroid has a good prognosis, but the occurrence of lymph node metastasis and distant metastasis is an important factor influencing prognosis. Therapy with 131I can be used to treat metastasis of DTC, lower the recurrence and mortality rates of patients, and prolong patients’ longevity, which is generally considered an effective method of treatment for this disease [7–9,13].
In our study, an analysis of 406 lymph nodes of 218 DTC patients was conducted. We found that the effective rate of 131I therapy was 88.07%, and the average accumulation dosage of 131I required for treatment was quite low, which is in agreement with other study reports [14,15]. This may be because the basic feature of thyroid cells’ iodine uptake was sustained in both metastases of papillary thyroid cancer and metastases of follicular thyroid cancer. Our study found that 131I internal radiation can be used to kill metastatic cancer cells effectively.
This study showed that 131I could effectively treat lymph node metastasis of DTC, but there are many influencing factors. The study looked at nine clinical factors that might influence the treatment efficacy of 131I, and found that distant metastasis, size of lymph nodes, HTG level, and condition of thyroid remnant ablation with 131I were independent factors influencing the efficacy of treatment. In a univariate analysis, age and the number of lymph nodes were also included as influencing factors, but were eliminated in a multivariate analysis, which might be correlated with the small number of clinical cases available and interference of other confounding factors. Of the confounding factors, thyroid tissue remnants and distant metastasis were found to be important in influencing the efficacy of treatment, likely because both remnant thyroid tissues and metastasis have the ability to uptake iodine, and thus reduce the effectiveness of iodine uptake of metastatic lymph nodes, especially under conditions where the iodine-uptake ability of remnant thyroid tissues is over 1,000 times that of metastatic tissue [16]. The HTG level is a specific marker used to identify the recurrence or metastasis of DTC [17–20]. It has also been proven to be an important factor influencing 131I treatment efficacy on metastasis of DTC, which is in line with the thyroid tissue remnants and distant metastasis. The size of the lymph node is also an important factor and when the diameter of metastatic lymph nodes is >2 cm it is difficult for 131I to totally eliminate them.
There were some limitations to our study. First, the sample size was small, and no detailed research or analysis was conducted based on age, staging, or other factors. Second, the follow-up was only short-term, and there was no analysis that showed the influence of 131I therapy on the survival period of DTC patients. Third, the retrospective design may have lead to unstable results due to the non-integrality of the data and the bias of inclusion and exclusion.
Conclusions
This study showed the efficacy of 131I for treating lymph node metastasis of DTC, but a comprehensive evaluation is needed on patients’ influencing factors to select optimal therapeutic schedules.
Footnotes
Competing interests
The authors have declared that no competing interests exist.
Source of support: This paper was partially supported by Health and Family Planning Commission of Hebei Province (20120113)
References
- 1.Kim TY, Kim WG, Kim WB, et al. Current status and future perspectives in differentiated thyroid cancer. Endocrinol Metab (Seoul) 2014;29:217–25. doi: 10.3803/EnM.2014.29.3.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16(12):1229–42. doi: 10.1089/thy.2006.16.1229. [DOI] [PubMed] [Google Scholar]
- 3.Simpson WJ, Panzarella T, Carruthers JS, et al. Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys. 1988;14:1063–75. doi: 10.1016/0360-3016(88)90381-1. [DOI] [PubMed] [Google Scholar]
- 4.Pitoia F, Bueno F, Cross G. Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancer. Clin Nucl Med. 2014;39:784–90. doi: 10.1097/RLU.0000000000000507. [DOI] [PubMed] [Google Scholar]
- 5.Long B, Yang M, Yang Z, et al. Assessment of radioiodine therapy efficacy for treatment of differentiated thyroid cancer patients with pulmonary metastasis undetected by chest computed tomography. Oncol Lett. 2016;11(2):965–68. doi: 10.3892/ol.2015.4034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214. doi: 10.1089/thy.2009.0110. [DOI] [PubMed] [Google Scholar]
- 7.Shaha AR. Prognostic factors in pap illary thyroid carcinoma and implications of large nodal metastasis. Surgery. 2004;135:237–39. doi: 10.1016/j.surg.2003.08.023. [DOI] [PubMed] [Google Scholar]
- 8.Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338(5):297–306. doi: 10.1056/NEJM199801293380506. [DOI] [PubMed] [Google Scholar]
- 9.Machens A, Hinze R, Thomusch O, et al. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg. 2002;26(1):22–28. doi: 10.1007/s00268-001-0176-3. [DOI] [PubMed] [Google Scholar]
- 10.Ronga G, Toteda M, D’Apollo R, et al. Lymph node metastases from differentiated thyroid carcinoma: Does radioiodine still play a role? Clin Ter. 2012;163(5):377–81. [PubMed] [Google Scholar]
- 11.Ye ZY, Wang H, Fu HL, et al. The study of influence factors on (131)I treatment of differentiated thyroid carcinoma withlymph node metastases. Clin Imaging. 2009;33(3):221–25. doi: 10.1016/j.clinimag.2008.09.006. [DOI] [PubMed] [Google Scholar]
- 12.Liu B, Kuang A, Huang R, et al. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: A prospective, randomized, single-blind, controlled trial. J Nucl Med. 2010;51(4):618–23. doi: 10.2967/jnumed.109.071449. [DOI] [PubMed] [Google Scholar]
- 13.Rosario PW, Ward LS, Carvalho GA, et al. Thyroid nodules and differentiated thyroid cancer: Update on the Brazilian consensus. Arq Bras Endocrinol Metabol. 2013;57:240–64. doi: 10.1590/s0004-27302013000400002. [DOI] [PubMed] [Google Scholar]
- 14.Ye ZY, Wang H, Fu HL, et al. The study of influence factors on (131)I treatment of differentiated thyroid carcinoma with lymph node metastases. Clin Imaging. 2009;33(3):221–25. doi: 10.1016/j.clinimag.2008.09.006. [DOI] [PubMed] [Google Scholar]
- 15.Zhu R, Yu Y, Lu H, et al. The clinical summary of 312 cases of differentiated thyroid carcinoma metastases with 131I treatment. Chin J Nucl Med. 2002;22:325–27. [Google Scholar]
- 16.Alessandri AJ, Goddard KJ, Blair GK, et al. Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. Med Pediatr Oncol. 2000;35:41–46. doi: 10.1002/1096-911x(200007)35:1<41::aid-mpo7>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
- 17.Vaisman A, Orlov S, Yip J, et al. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. Head Neck. 2010;32:689–98. doi: 10.1002/hed.21371. [DOI] [PubMed] [Google Scholar]
- 18.Rosario PW, Mineiro Filho AF, Prates BS, et al. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Thyroid. 2012;22:1140–43. doi: 10.1089/thy.2012.0190. [DOI] [PubMed] [Google Scholar]
- 19.Orlov S, Salari F, Kashat L, et al. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer. Endocrine. 2015;50:130–37. doi: 10.1007/s12020-015-0575-0. [DOI] [PubMed] [Google Scholar]
- 20.Rosario PW, Mourão GF. Is 131I ablation necessary for patients with low-risk papillary thyroid carcinoma and slightly elevated stimulated thyroglobulin after thyroidectomy? Arch Endocrinol Metab. 2016;60(1):5–8. doi: 10.1590/2359-3997000000158. [DOI] [PMC free article] [PubMed] [Google Scholar]